Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Specific Targeting of Zinc Transporter LIV-1 with Immunocytokine Containing Anti-LIV-1 VHH and Human IL-2 and Evaluation of its In vitro Antitumor Activity

Author(s): Rada Dehghan, Arezoo Beig Parikhani, Reza Ahangari Cohan, Mohammad Ali Shokrgozar, Esmat Mirabzadeh, Soheila Ajdary, Sirous Zeinali, Hajarossadat Ghaderi, Yeganeh Talebkhan* and Mahdi Behdani*

Volume 30, Issue 11, 2024

Published on: 12 March, 2024

Page: [868 - 876] Pages: 9

DOI: 10.2174/0113816128295195240305060103

Price: $65

Abstract

Background: Interleukin 2 (IL-2) is a vital cytokine in the induction of T and NK cell responses, the proliferation of CD8+ T cells, and the effective treatment of human cancers such as melanoma and renal cell carcinoma. However, widespread use of this cytokine is limited due to its short half-life, severe toxicity, lack of specific tumor targeting, and activation of Treg cells mediated by high-affinity interleukin-2 receptors.

Objective: In this study, a tumor-targeting LIV-1 VHH-mutIL2 immunocytokine with reduced CD25 (α chain of the high-affinity IL-2 receptor) binding activity was developed to improve IL-2 half-life by decreasing its renal infiltration in comparison with wild and mutant IL-2 molecules.

Methods: The recombinant immunocytokine was designed and expressed. The biological activity of the purified fusion protein was investigated in in vitro and in vivo experiments.

Results: The fusion protein represented specific binding to MCF7 (the breast cancer cell line) and more efficient cytotoxicity than wild-type IL-2 and mutant IL-2. The PK parameters of the recombinant immunocytokine were also improved in comparison to the IL-2 molecules.

Conclusion: The observed results showed that LIV1-mIL2 immunocytokine could be considered as an effective agent in the LIV-1-targeted treatment of cancers due to its longer half-life and stronger cytotoxicity.

« Previous Next »
[1]
Jiang T, Zhou C, Ren S. Role of IL-2 in cancer immunotherapy. OncoImmunology 2016; 5(6): e1163462.
[http://dx.doi.org/10.1080/2162402X.2016.1163462] [PMID: 27471638]
[2]
Chen X, Xu J, Guo Q, et al. therapeutic efficacy of an anti-PD-L1 antibody based immunocytokine in a metastatic mouse model of colorectal cancer. Biochem Biophys Res Commun 2016; 480(2): 160-5.
[http://dx.doi.org/10.1016/j.bbrc.2016.10.011] [PMID: 27720718]
[3]
Liao W, Lin JX, Leonard WJ. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 2013; 38(1): 13-25.
[http://dx.doi.org/10.1016/j.immuni.2013.01.004] [PMID: 23352221]
[4]
Carmenate T, Pacios A, Enamorado M, et al. Human IL-2 mutein with higher antitumor efficacy than wild type IL-2. J Immunol 2013; 190(12): 6230-8.
[http://dx.doi.org/10.4049/jimmunol.1201895] [PMID: 23677467]
[5]
Zhou Y, Quan G, Liu Y, et al. the application of Interleukin-2 family cytokines in tumor immunotherapy research. Front Immunol 2023; 14: 1090311.
[http://dx.doi.org/10.3389/fimmu.2023.1090311] [PMID: 36936961]
[6]
Skrombolas D, Frelinger JG. Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy. Expert Rev Clin Immunol 2014; 10(2): 207-17.
[http://dx.doi.org/10.1586/1744666X.2014.875856] [PMID: 24410537]
[7]
Schliemann C, Palumbo A, Zuberbühler K, et al. Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2. Blood 2009; 113(10): 2275-83.
[http://dx.doi.org/10.1182/blood-2008-05-160747] [PMID: 19005180]
[8]
Pasche N, Neri D. Immunocytokines: A novel class of potent armed antibodies. Drug Discov Today 2012; 17(11-12): 583-90.
[http://dx.doi.org/10.1016/j.drudis.2012.01.007] [PMID: 22289353]
[9]
Sondel PM, Gillies SD. Immunocytokines. Antibodies 2012; 1(2): 149-71.
[http://dx.doi.org/10.3390/antib1020149] [PMID: 24634778]
[10]
Ortiz-Sánchez E, Helguera G, Daniels TR, Penichet ML. Antibody–cytokine fusion proteins: Applications in cancer therapy. Expert Opin Biol ther 2008; 8(5): 609-32.
[http://dx.doi.org/10.1517/14712598.8.5.609] [PMID: 18407765]
[11]
Mårlind J, Kaspar M, Trachsel E, et al. Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy. Clin Cancer Res 2008; 14(20): 6515-24.
[http://dx.doi.org/10.1158/1078-0432.CCR-07-5041] [PMID: 18927291]
[12]
Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer 2012; 12(4): 278-87.
[http://dx.doi.org/10.1038/nrc3236] [PMID: 22437872]
[13]
Gillies SD, Lan Y, Hettmann T, et al. A low-toxicity IL-2-based immunocytokine retains antitumor activity despite its high degree of IL-2 receptor selectivity. Clin Cancer Res 2011; 17(11): 3673-85.
[http://dx.doi.org/10.1158/1078-0432.CCR-10-2921] [PMID: 21531812]
[14]
Connor JP, Cristea MC, Lewis NL, et al. A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM- positive advanced solid tumors. BMC Cancer 2013; 13(1): 20.
[http://dx.doi.org/10.1186/1471-2407-13-20] [PMID: 23320927]
[15]
Gout DY, Groen LS, van Egmond M. the present and future of immunocytokines for cancer treatment. Cell Mol Life Sci 2022; 79(10): 509.
[http://dx.doi.org/10.1007/s00018-022-04514-9] [PMID: 36066630]
[16]
Polakis P. Antibody drug conjugates for cancer therapy. Pharmacol Rev 2016; 68(1): 3-19.
[http://dx.doi.org/10.1124/pr.114.009373] [PMID: 26589413]
[17]
Arezumand R, Alibakhshi A, Ranjbari J, Ramazani A, Muyldermans S. Nanobodies as novel agents for targeting angiogenesis in solid cancers. Front Immunol 2017; 8: 1746.
[http://dx.doi.org/10.3389/fimmu.2017.01746] [PMID: 29276515]
[18]
Schumacher D, Helma J, Schneider AFL, Leonhardt H, Hackenberger CPR. Nanobodies: Chemical functionalization strategies and intracellular applications. Angew Chem Int Ed 2018; 57(9): 2314-33.
[http://dx.doi.org/10.1002/anie.201708459] [PMID: 28913971]
[19]
Spadiut O, Capone S, Krainer F, Glieder A, Herwig C. Microbials for the production of monoclonal antibodies and antibody fragments. Trends Biotechnol 2014; 32(1): 54-60.
[http://dx.doi.org/10.1016/j.tibtech.2013.10.002] [PMID: 24183828]
[20]
Hamers-Casterman C, Atarhouch T, Muyldermans S, et al. Naturally occurring antibodies devoid of light chains. Nature 1993; 363(6428): 446-8.
[http://dx.doi.org/10.1038/363446a0] [PMID: 8502296]
[21]
Oliveira S, Heukers R, Sornkom J, Kok RJ, van en Henegouwen BPMP. Targeting tumors with nanobodies for cancer imaging and therapy. J Control Release 2013; 172(3): 607-17.
[http://dx.doi.org/10.1016/j.jconrel.2013.08.298] [PMID: 24035975]
[22]
Siontorou CG. Nanobodies as novel agents for disease diagnosis and therapy. Int J Nanomed 2013; 8: 4215-27.
[http://dx.doi.org/10.2147/IJN.S39428] [PMID: 24204148]
[23]
Muyldermans S. Nanobodies: Natural single-domain antibodies. Annu Rev Biochem 2013; 82(1): 775-97.
[http://dx.doi.org/10.1146/annurev-biochem-063011-092449] [PMID: 23495938]
[24]
Lomedasht KF, Muyldermans S, Anbouhi HM, Behdani M. Design of a humanized anti vascular endothelial growth factor nanobody and evaluation of its in vitro function. Iran J Basic Med Sci 2018; 21(3): 260-6.
[PMID: 29511492]
[25]
Sussman D, Smith LM, Anderson ME, et al. SGN-LIV1A: A novel antibody-drug conjugate targeting LIV-1 for the treatment of metastatic breast cancer. Mol Cancer ther 2014; 13(12): 2991-3000.
[http://dx.doi.org/10.1158/1535-7163.MCT-13-0896] [PMID: 25253783]
[26]
Unno J, Masamune A, Hamada S, Shimosegawa T. The zinc transporter LIV-1 is a novel regulator of stemness in pancreatic cancer cells. Scand J Gastroenterol 2014; 49(2): 215-21.
[http://dx.doi.org/10.3109/00365521.2013.865075] [PMID: 24294832]
[27]
Shen R, Xie F, Shen H, et al. Negative correlation of LIV-1 and E-cadherin expression in hepatocellular carcinoma cells. PLoS One 2013; 8(2): e56542.
[http://dx.doi.org/10.1371/journal.pone.0056542] [PMID: 23437163]
[28]
Ghaderi H, Noormohammadi Z, Anbouhi HM, Lomedasht KF, Behdani M. Development of camelid monoclonal nanobody against SLC39A6 zinc transporter protein. Iran J Basic Med Sci 2021; 24(12): 1726-33.
[PMID: 35432806]
[29]
Parikhani BA, Bagherzadeh K, Dehghan R, et al. Human IL-2Rɑ subunit binding modulation of IL-2 through a decline in electrostatic interactions: A computational and experimental approach. PLoS One 2022; 17(2): e0264353.
[http://dx.doi.org/10.1371/journal.pone.0264353] [PMID: 35213635]
[30]
Dehghan R, Parikhani BA, Zeinali S, et al. Efficacy and antitumor activity of a mutant type of interleukin 2. Sci Rep 2022; 12(1): 5376.
[http://dx.doi.org/10.1038/s41598-022-09278-7] [PMID: 35354847]
[31]
Sim GC, Liu C, Wang E, et al. IL2 variant circumvents ICOS+ regulatory T-cell expansion and promotes NK cell activation. Cancer Immunol Res 2016; 4(11): 983-94.
[http://dx.doi.org/10.1158/2326-6066.CIR-15-0195] [PMID: 27697858]
[32]
Carmenate T, Ortíz Y, Enamorado M, et al. Blocking IL-2 signal in vivo with an IL-2 antagonist reduces tumor growth through the control of regulatory T cells. J Immunol 2018; 200(10): 3475-84.
[http://dx.doi.org/10.4049/jimmunol.1700433] [PMID: 29618524]
[33]
Beyer M, Schumak B, Weihrauch MR, et al. In vivo expansion of naïve CD4+ CD25(high) FOXP3+ regulatory T cells in patients with colorectal carcinoma after IL-2 administration. PLoS One 2012; 7(1): e30422.
[http://dx.doi.org/10.1371/journal.pone.0030422] [PMID: 22276195]
[34]
Chen X, Ai X, Wu C, et al. A novel human IL-2 mutein with minimal systemic toxicity exerts greater antitumor efficacy than wild- type IL-2. Cell Death Dis 2018; 9(10): 989.
[http://dx.doi.org/10.1038/s41419-018-1047-2] [PMID: 30250191]
[35]
Tang A, Harding F. the challenges and molecular approaches surrounding interleukin-2-based therapeutics in cancer. Cytokine X 2019; 1(1): 100001.
[http://dx.doi.org/10.1016/j.cytox.2018.100001]
[36]
Levin AM, Bates DL, Ring AM, et al. Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’. Nature 2012; 484(7395): 529-33.
[http://dx.doi.org/10.1038/nature10975] [PMID: 22446627]
[37]
Hu P, Mizokami M, Ruoff G, Khawli LA, Epstein AL. Generation of low-toxicity interleukin-2 fusion proteins devoid of vasopermeability activity. Blood 2003; 101(12): 4853-61.
[http://dx.doi.org/10.1182/blood-2002-10-3089] [PMID: 12609842]
[38]
Klein C, Waldhauer I, Nicolini VG, et al. Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. OncoImmunology 2017; 6(3): e1277306.
[http://dx.doi.org/10.1080/2162402X.2016.1277306] [PMID: 28405498]
[39]
Kim Y, Kim HS, Cui ZY, et al. Clinicopathological implications of EpCAM expression in adenocarcinoma of the lung. Anticancer Res 2009; 29(5): 1817-22.
[PMID: 19443410]
[40]
Connor JP, Felder M, Hank J, et al. Ex vivo evaluation of anti-EpCAM immunocytokine huKS-IL2 in ovarian cancer. J Immunother 2004; 27(3): 211-9.
[http://dx.doi.org/10.1097/00002371-200405000-00005] [PMID: 15076138]
[41]
Went PTH, Lugli A, Meier S, et al. Frequent EpCam protein expression in human carcinomas. Hum Pathol 2004; 35(1): 122-8.
[http://dx.doi.org/10.1016/j.humpath.2003.08.026] [PMID: 14745734]
[42]
Buhtoiarov IN, Neal ZC, Gan J, et al. Differential internalization of hu14.18-IL2 immunocytokine by NK and tumor cell: Impact on conjugation, cytotoxicity, and targeting. J Leukoc Biol 2011; 89(4): 625-38.
[http://dx.doi.org/10.1189/jlb.0710422] [PMID: 21248148]
[43]
Sun Z, Ren Z, Yang K, et al. A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control. Nat Commun 2019; 10(1): 3874.
[http://dx.doi.org/10.1038/s41467-019-11782-w] [PMID: 31462678]
[44]
Heaton KM, Ju G, Grimm EA. Human interleukin 2 analogues that preferentially bind the intermediate-affinity interleukin 2 receptor lead to reduced secondary cytokine secretion: Implications for the use of these interleukin 2 analogues in cancer immunotherapy. Cancer Res 1993; 53(11): 2597-602.
[PMID: 8495422]
[45]
Gutbrodt KL, Schliemann C, Giovannoni L, Frey K, Pabst T, Klapper W. Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia. Sci Transl Med 2013; 5(201): 201ra118-.
[http://dx.doi.org/10.1126/scitranslmed.3006221]
[46]
Krieg C, Létourneau S, Pantaleo G, Boyman O. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc Natl Acad Sci 2010; 107(26): 11906-11.
[http://dx.doi.org/10.1073/pnas.1002569107] [PMID: 20547866]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy